| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.3 | 1e-06 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.23 | 1e-06 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.23 | 1e-06 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.24 | 3e-05 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.16 | 0.0003 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0006 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0007 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0008 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0008 |